162 related articles for article (PubMed ID: 33287648)
1. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations in CTNNB1 in aldosterone producing adenomas.
Åkerström T; Maharjan R; Sven Willenberg H; Cupisti K; Ip J; Moser A; Stålberg P; Robinson B; Alexander Iwen K; Dralle H; Walz MK; Lehnert H; Sidhu S; Gomez-Sanchez C; Hellman P; Björklund P
Sci Rep; 2016 Jan; 6():19546. PubMed ID: 26815163
[TBL] [Abstract][Full Text] [Related]
3. Colocalization of Wnt/β-Catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone-producing Adenoma.
De Sousa K; Abdellatif AB; Giscos-Douriez I; Meatchi T; Amar L; Fernandes-Rosa FL; Boulkroun S; Zennaro MC
J Clin Endocrinol Metab; 2022 Jan; 107(2):419-434. PubMed ID: 34570225
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
[TBL] [Abstract][Full Text] [Related]
5. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
6. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.
Berthon A; Drelon C; Ragazzon B; Boulkroun S; Tissier F; Amar L; Samson-Couterie B; Zennaro MC; Plouin PF; Skah S; Plateroti M; Lefèbvre H; Sahut-Barnola I; Batisse-Lignier M; Assié G; Lefrançois-Martinez AM; Bertherat J; Martinez A; Val P
Hum Mol Genet; 2014 Feb; 23(4):889-905. PubMed ID: 24087794
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
[TBL] [Abstract][Full Text] [Related]
8. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
[TBL] [Abstract][Full Text] [Related]
9. lncRNA FLVCR1-AS1 silencing inhibits lung cancer cell proliferation, migration, and invasion by inhibiting the activity of the Wnt/β-catenin signaling pathway.
Lin H; Shangguan Z; Zhu M; Bao L; Zhang Q; Pan S
J Cell Biochem; 2019 Jun; 120(6):10625-10632. PubMed ID: 30697812
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
11. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
14. AXIN genetic analysis in adrenocortical carcinomas updated.
Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
[TBL] [Abstract][Full Text] [Related]
15. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
[TBL] [Abstract][Full Text] [Related]
16. Genetic Characterization of GnRH/LH-Responsive Primary Aldosteronism.
Gagnon N; Cáceres-Gorriti KY; Corbeil G; El Ghoyareb N; Ludwig N; Latour M; Lacroix A; Bourdeau I
J Clin Endocrinol Metab; 2018 Aug; 103(8):2926-2935. PubMed ID: 29726953
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes.
Wu VC; Wang SM; Chueh SJ; Yang SY; Huang KH; Lin YH; Wang JJ; Connolly R; Hu YH; Gomez-Sanchez CE; Peng KY; Wu KD
Sci Rep; 2017 Jan; 7():39121. PubMed ID: 28102204
[TBL] [Abstract][Full Text] [Related]
18. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
Chapman A; Durand J; Ouadi L; Bourdeau I
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.
Zhou J; Azizan EAB; Cabrera CP; Fernandes-Rosa FL; Boulkroun S; Argentesi G; Cottrell E; Amar L; Wu X; O'Toole S; Goodchild E; Marker A; Senanayake R; Garg S; Åkerström T; Backman S; Jordan S; Polubothu S; Berney DM; Gluck A; Lines KE; Thakker RV; Tuthill A; Joyce C; Kaski JP; Karet Frankl FE; Metherell LA; Teo AED; Gurnell M; Parvanta L; Drake WM; Wozniak E; Klinzing D; Kuan JL; Tiang Z; Gomez Sanchez CE; Hellman P; Foo RSY; Mein CA; Kinsler VA; Björklund P; Storr HL; Zennaro MC; Brown MJ
Nat Genet; 2021 Sep; 53(9):1360-1372. PubMed ID: 34385710
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
